Status:
COMPLETED
A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's Disease
Lead Sponsor:
Biogen
Collaborating Sponsors:
Elan Pharmaceuticals
Conditions:
Crohn's Disease
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The purpose of this trial is to evaluate natalizumab in individuals with moderately to severely active Crohn's Disease.
Detailed Description
Natalizumab is a humanized monoclonal antibody currently being investigated as a potential treatment for Crohn's disease. It is believed to work by preventing white blood cells from moving from the bl...
Eligibility Criteria
Inclusion
- Males and females 18 years of age or older
- Diagnosis of Crohn's disease for at least 6 months
- Females must not be pregnant or breastfeeding
- Must not have previously taken natalizumab
- Use of some other Crohn's disease medications is permitted, but will be closely supervised
Exclusion
Key Trial Info
Start Date :
March 1 2004
Trial Type :
INTERVENTIONAL
End Date :
March 1 2005
Estimated Enrollment :
462 Patients enrolled
Trial Details
Trial ID
NCT00078611
Start Date
March 1 2004
End Date
March 1 2005
Last Update
June 16 2016
Active Locations (75)
Enter a location and click search to find clinical trials sorted by distance.
1
Harmony Clinical Research
Oro Valley, Arizona, United States, 85739
2
Advanced Clinical Therapeutics
Tucson, Arizona, United States, 85712
3
Advanced Clinical Research Institute
Anaheim, California, United States, 92801
4
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048